ANGLE’s H121 results confirm progress of its proprietary Parsortix cancer diagnostic platform across multiple fronts. Whilst attention inevitably focusses on the expected upcoming FDA approval for use in metastatic breast cancer, important progress has been achieved with developing the ovarian cancer LDT (Laboratory Developed Test). UK and US clinical laboratories, created ahead of schedule, are anticipated to receive certification by year-end. This will drive nearer term revenues from pharma services, demonstrate the clinical value, and validate the proposition for larger commercial labs. Collectively these efforts will help shape Parsortix’s positioning in the emerging, and dynamic, liquid biopsy market. We value ANGLE at £581m ($755m), 248p/share.

01 Oct 2021
Poised to disrupt existing tumour assay protocols

Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Poised to disrupt existing tumour assay protocols
ANGLE plc (AGL:LON) | 19.5 0 0.0% | Mkt Cap: 50.8m
- Published:
01 Oct 2021 -
Author:
Franc Gregori | Lala Gregorek -
Pages:
10 -
ANGLE’s H121 results confirm progress of its proprietary Parsortix cancer diagnostic platform across multiple fronts. Whilst attention inevitably focusses on the expected upcoming FDA approval for use in metastatic breast cancer, important progress has been achieved with developing the ovarian cancer LDT (Laboratory Developed Test). UK and US clinical laboratories, created ahead of schedule, are anticipated to receive certification by year-end. This will drive nearer term revenues from pharma services, demonstrate the clinical value, and validate the proposition for larger commercial labs. Collectively these efforts will help shape Parsortix’s positioning in the emerging, and dynamic, liquid biopsy market. We value ANGLE at £581m ($755m), 248p/share.